Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui1, E.B. Garon2, J.W. Goldman2, N.B. Leighl3, M.D. Hellmann4, A. Patnaik5, L. Gandhi6, J.P. Eder7, M.-J. Ahn8, L. Horn9, E. Felip10, E. Carcereny11, R. Rangwala12, G.M. Lubiniecki12, J. Zhang12, K. Emancipator12, C. Roach13, N.A. Rizvi14
1Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia
2Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, USA
3Department of Medicine, Princess Margaret Cancer Centre, Toronto, Canada
4Hematology/Oncology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York
5Oncology and Hematology Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio
6Hematology/Oncology, Dana-Farber Cancer Institute, Boston
7Medical Oncology, Yale University, New Haven, USA
8Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
9Thoracic Oncology, Vanderbilt Ingram Cancer Center, Nashville, USA
10Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona
11Medical Oncology, Catalan Institute of Oncology Badalona, Badalona, Spain
12Medical Oncology, Merck & Co., Inc., Kenilworth
13Companion Diagnostics, Dako, an Agilent Technologies Company, Carpinteria
14Thoracic Oncology, Columbia University, New York, USA